S&P Futures
4,157.75+2.25(+0.05%)Dow Futures
33,953.00-5.00(-0.01%)Nasdaq Futures
13,919.75+22.50(+0.16%)
Stealth BioTherapeutics Corp (MITO)
1.1600 +0.08 (7.41%)
Pre-Market: 4:24AM EDT
Chart Events
Performance Outlook
| Previous Close | 1.1200 |
| Open | 1.1300 |
| Bid | 0.0000 x 3200 |
| Ask | 0.0000 x 900 |
| Day's Range | 1.0700 - 1.1599 |
| 52 Week Range | 1.0700 - 2.5800 |
| Volume | 215,260 |
| Avg. Volume | 433,353 |
| Market Cap | 62.291M |
| Beta (5Y Monthly) | 2.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2400 |
| Earnings Date | Nov 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.33 |
- PR Newswire
Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2020 and announced recent business highlights.
- ACCESSWIRE
Stealth BioTherapeutics Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Stealth BioTherapeutics Corp. (NASDAQ:MITO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on April 6, 2021 at 8:30 AM Eastern Time.
- PR Newswire
Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report full year 2020 financial results on Tuesday, April 6, 2021, before the market opens.
